Expression of TRAIL, DR4, and DR5 in Bladder Cancer: Correlation with Response to Adjuvant Therapy and Implications of Prognosis
Yongnan Li,Xiudong Jin,Jinhua Li,Xinghua Jin,Jianbo Yu,Xiaodong Sun,Yanhui Chu,Chunyan Xu,Xiaoxia Li,Xijun Wang,Yoshiyuki Kakehi,Xiuxian Wu
DOI: https://doi.org/10.1016/j.urology.2011.11.011
IF: 2.633
2012-01-01
Urology
Abstract:OBJECTIVES To explore the interrelationship of human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its death receptors DR4 and DR5 expressions level with patient prognosis and the response to adjuvant therapy in bladder cancer, the synergism function that is between chemotherapy and TRAIL on apoptosis induction in tumor cells. METHODS The expression of TRAIL, DR4, and DR5 was studied using immunohistochemistry of paraffin-embedded tumor specimens from 229 bladder cancer patients who had undergone transurethral resection. RESULTS Cytoplasmic TRAIL, DR4, and DR5 expressions were detected in 35%, 75.1%, and 74.2% of bladder cancer patients, respectively. Patients with bladder cancer with either high DR4 or DR5 expression had a significantly longer postoperative recurrence-free rate than those with low expression of both during the 10-year follow-up. Multivariate analysis revealed that the expression of DR4 (P < .001), DR5 (P < .001) and epirubicin therapy (P = .034) were independent prognostic indicators of bladder cancer. Furthermore, epirubicin therapy significantly improved recurrence-free rate for the patients with DR4-high (P = .006) or DR5-high (P = .042) tumor. CONCLUSIONS The results of the present study have shown for the first time that a combination of DR4 and DR5 expression have significant value in predicting the prognosis of bladder cancer. In addition, patients with high expression of both DR4 and DR5 might benefit from epirubicin therapy. UROLOGY 79: 968.e7-968.e15, 2012. (C) 2012 Elsevier Inc.